Condition
Septal Defect, Atrial
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (3)
P 3 (1)
Trial Status
Completed2
Unknown1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04395027Phase 3WithdrawnPrimary
Iatrogenic Atrial Septal Defect Study (iASD)
NCT01711983Not ApplicableCompletedPrimary
Safety and Efficacy of the GORE® Septal Occluder to Treat Ostium Secundum Atrial Septal Defects
NCT00581308Not ApplicableCompletedPrimary
Long-term Safety Study of the GORE® HELEX® Septal Occluder
NCT03373929Not ApplicableUnknown
Stitch Closure of PFO and Septal Repair
Showing all 4 trials